Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Official title

ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Study identification

NCT ID

NCT07181109

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Alnylam Pharmaceuticals

Industry

Enrollment

11,000 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 21, 2025

Primary completion

Sep 29, 2030

Completion

Sep 29, 2030

Last update posted

Apr 16, 2026

2025 – 2030

United States locations

U.S. sites

229

U.S. states

35

U.S. cities

191

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 361 non-U.S. sites.